Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-FGFR4 Nb1 CAR-T
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-FGFR4 Nb1 CAR-T is a type of Chimeric Antigen Receptor T (CAR-T) cell therapy that utilizes nanobodies (Nb1) to target Fibroblast Growth Factor Receptor 4 (FGFR4). This therapy involves genetically engineering a patient's T cells to express a CAR that specifically recognizes and binds to FGFR4, an oncogenic receptor tyrosine kinase found on the surface of certain cancer cells. The binding of the CAR-T cells to FGFR4-expressing tumor cells is intended to induce selective toxicity and eliminate these cancer cells. This nanobody-based CAR-T technology is being developed for the treatment of hepatocellular carcinoma (HCC).
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on anti-FGFR4 Nb1 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-FGFR4 Nb1 CAR-T.